Clinical effects of continuous sequential therapy of femoston in 121 cases of menopausal syndrome
doi: 10.3969/j.issn.1006-0111.2016.06.019
- Received Date: 2016-08-31
- Rev Recd Date: 2016-10-14
-
Key words:
- femoston /
- hormone replacement therapy /
- menopausal syndrome
Abstract: Objective To explore the clinical efficacy and safety of continuous sequential hormone replacement therapy of femoston for menopausal syndrome. Methods 121 cases of menopausal syndrome at expert outpatient service in our hospital from January 2014 to October 2015 received hormone replacement therapy of femoston for 24 weeks. Before and after treatment, Kupperman score, blood follicle stimulating hormone (FSH), estradiol (E2), luteinizing hormone (LH) and endometrial thickness were determined. Results With the prolonging of treatment time, patient's menopausal symptoms gradually relieved. Kupperman scores were declining. After 6 courses of treatment, patient's menopausal symptoms completely eased. Kupperman scores decreased by 95.0% (P<0.01), serum FSH and LH decreased significantly (P < 0.05 and P < 0.01) and serum E2 increased notably (P<0.01) without endometrial thickness changes (P>0.05). Conclusion Continuous sequential therapy of femoston can effectively relieve menopausal syndrome and control the menstrual cycle and the endocrine level without stimulating the endometrium excessively.
Citation: | LOU Huiping, CHAI Suping, WANG Min. Clinical effects of continuous sequential therapy of femoston in 121 cases of menopausal syndrome[J]. Journal of Pharmaceutical Practice and Service, 2016, 34(6): 560-562. doi: 10.3969/j.issn.1006-0111.2016.06.019 |